Skip to main content
Erschienen in: European Radiology 7/2018

07.02.2018 | Interventional

Ablation of colorectal liver metastasis: Interaction of ablation margins and RAS mutation profiling on local tumour progression-free survival

verfasst von: Marco Calandri, Suguru Yamashita, Carlo Gazzera, Paolo Fonio, Andrea Veltri, Sara Bustreo, Rahul A. Sheth, Steven M. Yevich, Jean-Nicolas Vauthey, Bruno C. Odisio

Erschienen in: European Radiology | Ausgabe 7/2018

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To investigate effects of ablation margins on local tumour progression-free survival (LTPFS) according to RAS status in patients with colorectal liver metastases (CLM).

Methods

This two-institution retrospective study from 2005–2016 included 136 patients (91 male, median age 60 years) with 218 ablated CLM. LTPFS was performed using the Kaplan–Meier method and evaluated with the log-rank test. Uni/multivariate analyses were performed using Cox-regression models.

Results

Three-year LTPFS rates for CLM with minimal ablation margin ≤10 mm were significantly worse than those with >10 mm in both mutant-RAS (29% vs. 48%, p=0.038) and wild-type RAS (70% vs. 94%, p=0.039) subgroups. Three-year LTPFS rates of mutant-RAS were significantly worse than wild-type RAS in both CLM subgroups with minimal ablation margin ≤10 mm (29% vs. 70%, p<0.001) and >10 mm (48% vs. 94%, p=0.006). Predictors of worse LTPFS were ablation margins ≤10 mm (HR: 2.17, 95% CI 1.2–4.1, p=0.007), CLM size ≥2 cm (1.80, 1.1–2.8, p=0.017) and mutant-RAS (2.85, 1.7–4.6, p<0.001).

Conclusions

Minimal ablation margin and RAS status interact as independent predictors of LTPFS following CLM ablation. While minimal ablation margins >10 mm should be always the procedural goal, this becomes especially critical for mutant-RAS CLM.

Key Points

RAS and ablation margins are predictors of local tumour progression-free survival.
Ablation margin >10 mm, always desirable, is crucial for mutant RAS metastases.
Interventional radiologists should be aware of RAS status to optimize LTPFS.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Shady W, Petre EN, Gonen M et al (2016) Percutaneous Radiofrequency Ablation of Colorectal Cancer Liver Metastases: Factors Affecting Outcomes--A 10-year Experience at a Single Center. Radiology 278:601–611.CrossRefPubMed Shady W, Petre EN, Gonen M et al (2016) Percutaneous Radiofrequency Ablation of Colorectal Cancer Liver Metastases: Factors Affecting Outcomes--A 10-year Experience at a Single Center. Radiology 278:601–611.CrossRefPubMed
2.
Zurück zum Zitat de Baere T, Tselikas L, Yevich S et al (2017) The role of image-guided therapy in the management of colorectal cancer metastatic disease. Eur J Cancer 75:231–242.CrossRefPubMed de Baere T, Tselikas L, Yevich S et al (2017) The role of image-guided therapy in the management of colorectal cancer metastatic disease. Eur J Cancer 75:231–242.CrossRefPubMed
3.
Zurück zum Zitat Solbiati L, Ahmed M, Cova L et al (2012) Small liver colorectal metastases treated with percutaneous radiofrequency ablation: local response rate and long-term survival with up to 10-year follow-up. Radiology 265:958–968. CrossRefPubMed Solbiati L, Ahmed M, Cova L et al (2012) Small liver colorectal metastases treated with percutaneous radiofrequency ablation: local response rate and long-term survival with up to 10-year follow-up. Radiology 265:958–968. CrossRefPubMed
4.
Zurück zum Zitat Sofocleous CT, Petre EN, Gonen M et al (2011) CT-guided Radiofrequency Ablation as a Salvage Treatment of Colorectal Cancer Hepatic Metastases Developing after Hepatectomy. J Vasc Interv Radiol 22:755–761. CrossRefPubMedPubMedCentral Sofocleous CT, Petre EN, Gonen M et al (2011) CT-guided Radiofrequency Ablation as a Salvage Treatment of Colorectal Cancer Hepatic Metastases Developing after Hepatectomy. J Vasc Interv Radiol 22:755–761. CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Van Cutsem E, Cervantes A, Adam R et al (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol Off J Eur Soc Med Oncol 27:1386–1422. CrossRef Van Cutsem E, Cervantes A, Adam R et al (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol Off J Eur Soc Med Oncol 27:1386–1422. CrossRef
7.
Zurück zum Zitat Gillams AR, Lees WR (2009) Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. Eur Radiol 19:1206–1213. CrossRefPubMed Gillams AR, Lees WR (2009) Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. Eur Radiol 19:1206–1213. CrossRefPubMed
8.
Zurück zum Zitat Wang X, Sofocleous CT, Erinjeri JP et al (2013) Margin size is an independent predictor of local tumor progression after ablation of colon cancer liver metastases. Cardiovasc Intervent Radiol 36:166–175. CrossRefPubMed Wang X, Sofocleous CT, Erinjeri JP et al (2013) Margin size is an independent predictor of local tumor progression after ablation of colon cancer liver metastases. Cardiovasc Intervent Radiol 36:166–175. CrossRefPubMed
9.
Zurück zum Zitat Veltri A, Sacchetto P, Tosetti I et al (2008) Radiofrequency Ablation of Colorectal Liver Metastases: Small Size Favorably Predicts Technique Effectiveness and Survival. Cardiovasc Intervent Radiol 31:948–956.CrossRefPubMed Veltri A, Sacchetto P, Tosetti I et al (2008) Radiofrequency Ablation of Colorectal Liver Metastases: Small Size Favorably Predicts Technique Effectiveness and Survival. Cardiovasc Intervent Radiol 31:948–956.CrossRefPubMed
10.
Zurück zum Zitat Odisio BC, Yamashita S, Huang SY et al (2017) Local tumour progression after percutaneous ablation of colorectal liver metastases according to RAS mutation status. Br J Surg 104:760–768.CrossRefPubMedPubMedCentral Odisio BC, Yamashita S, Huang SY et al (2017) Local tumour progression after percutaneous ablation of colorectal liver metastases according to RAS mutation status. Br J Surg 104:760–768.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Amado RG, Wolf M, Peeters M et al (2008) Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer. J Clin Oncol 26:1626–1634.CrossRefPubMed Amado RG, Wolf M, Peeters M et al (2008) Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer. J Clin Oncol 26:1626–1634.CrossRefPubMed
12.
Zurück zum Zitat Karapetis CS, Khambata-Ford S, Jonker DJ et al (2008) K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer. N Engl J Med 359:1757–1765. CrossRefPubMed Karapetis CS, Khambata-Ford S, Jonker DJ et al (2008) K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer. N Engl J Med 359:1757–1765. CrossRefPubMed
13.
Zurück zum Zitat Pollock CB, Shirasawa S, Sasazuki T et al (2005) Oncogenic K-RAS is required to maintain changes in cytoskeletal organization, adhesion, and motility in colon cancer cells. Cancer Res 65:1244–1250. CrossRefPubMed Pollock CB, Shirasawa S, Sasazuki T et al (2005) Oncogenic K-RAS is required to maintain changes in cytoskeletal organization, adhesion, and motility in colon cancer cells. Cancer Res 65:1244–1250. CrossRefPubMed
14.
Zurück zum Zitat Brudvik KW, Mise Y, Chung MH et al (2016) RAS Mutation Predicts Positive Resection Margins and Narrower Resection Margins in Patients Undergoing Resection of Colorectal Liver Metastases. Ann Surg Oncol 23:2635–2643. CrossRefPubMedPubMedCentral Brudvik KW, Mise Y, Chung MH et al (2016) RAS Mutation Predicts Positive Resection Margins and Narrower Resection Margins in Patients Undergoing Resection of Colorectal Liver Metastases. Ann Surg Oncol 23:2635–2643. CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Ahmed M, Solbiati L, Brace CL et al (2014) Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update. J Vasc Interv Radiol JVIR 25:1691–1705.e4. CrossRefPubMed Ahmed M, Solbiati L, Brace CL et al (2014) Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update. J Vasc Interv Radiol JVIR 25:1691–1705.e4. CrossRefPubMed
16.
Zurück zum Zitat Knijn N, Mekenkamp LJM, Klomp M et al (2011) KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer 104:1020–1026.CrossRefPubMedPubMedCentral Knijn N, Mekenkamp LJM, Klomp M et al (2011) KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer 104:1020–1026.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Baas JM, Krens LL, Guchelaar H-J et al (2011) Concordance of Predictive Markers for EGFR Inhibitors in Primary Tumors and Metastases in Colorectal Cancer: A Review. The Oncologist 16:1239–1249.CrossRefPubMedPubMedCentral Baas JM, Krens LL, Guchelaar H-J et al (2011) Concordance of Predictive Markers for EGFR Inhibitors in Primary Tumors and Metastases in Colorectal Cancer: A Review. The Oncologist 16:1239–1249.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Gillams A, Goldberg N, Ahmed M et al (2015) Thermal ablation of colorectal liver metastases: a position paper by an international panel of ablation experts, the interventional oncology sans frontières meeting 2013. Eur Radiol 25:3438–3454.CrossRefPubMedPubMedCentral Gillams A, Goldberg N, Ahmed M et al (2015) Thermal ablation of colorectal liver metastases: a position paper by an international panel of ablation experts, the interventional oncology sans frontières meeting 2013. Eur Radiol 25:3438–3454.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Pathak S, Jones R, Tang JMF et al (2011) Ablative therapies for colorectal liver metastases: a systematic review: Ablation for colorectal liver metastases. Colorectal Dis 13:e252–e265.CrossRefPubMed Pathak S, Jones R, Tang JMF et al (2011) Ablative therapies for colorectal liver metastases: a systematic review: Ablation for colorectal liver metastases. Colorectal Dis 13:e252–e265.CrossRefPubMed
20.
Zurück zum Zitat Hur H, Ko YT, Min BS et al (2009) Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. Am J Surg 197:728–736.CrossRefPubMed Hur H, Ko YT, Min BS et al (2009) Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. Am J Surg 197:728–736.CrossRefPubMed
21.
Zurück zum Zitat Aloia TA (2006) Solitary Colorectal Liver Metastasis: Resection Determines Outcome. Arch Surg 141:460. CrossRefPubMed Aloia TA (2006) Solitary Colorectal Liver Metastasis: Resection Determines Outcome. Arch Surg 141:460. CrossRefPubMed
Metadaten
Titel
Ablation of colorectal liver metastasis: Interaction of ablation margins and RAS mutation profiling on local tumour progression-free survival
verfasst von
Marco Calandri
Suguru Yamashita
Carlo Gazzera
Paolo Fonio
Andrea Veltri
Sara Bustreo
Rahul A. Sheth
Steven M. Yevich
Jean-Nicolas Vauthey
Bruno C. Odisio
Publikationsdatum
07.02.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
European Radiology / Ausgabe 7/2018
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-017-5273-2

Weitere Artikel der Ausgabe 7/2018

European Radiology 7/2018 Zur Ausgabe

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärztinnen und Psychotherapeuten.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.